Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.48 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 2/20 | 0.46 |
| ▸ | CES1 | P23141 | 2/20 | 0.46 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | POLQ | O75417 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3742708 | 1.00 | EPHX2 (0.50) | EPHX2NPC1JAK2RAB9APAX8 | |
| SCHEMBL10407826 | 0.87 | NPC1 (0.53) | EPHX2NPC1JAK2RAB9APAX8 | |
| SCHEMBL11515226 | 0.87 | NPC1 (0.53) | EPHX2NPC1JAK2RAB9APAX8 | |
| SCHEMBL26614645 | 0.87 | NPC1 (0.53) | EPHX2NPC1JAK2RAB9APAX8 | |
| SCHEMBL4130517 | 0.87 | NPC1 (0.53) | EPHX2NPC1JAK2RAB9APAX8 | |
| SCHEMBL26614476 | 0.87 | NPC1 (0.53) | EPHX2NPC1JAK2RAB9APAX8 | |
| SCHEMBL3735933 | 0.86 | NPC1 (0.49) | EPHX2NPC1JAK2RAB9APAX8 | |
| SCHEMBL27351408 | 0.85 | CES2 (0.50) | EPHX2NPC1JAK2RAB9APAX8 | |
| SCHEMBL13678978 | 0.85 | GAA (0.48) | EPHX2NPC1RAB9AHAO1POLQ | |
| SCHEMBL3748980 | 0.82 | POLB (0.42) | EPHX2HAO1CES2CES1ASAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280034-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2010-11-04 | — | — | US | disclosed |
| US-7338969-B2 | Modulation of pathogenicity | QUONOVA, LLC (US) | 2008-03-04 | — | — | US | disclosed |
| US-20070208012-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-09-06 | — | — | US | disclosed |
| US-20070203128-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-08-30 | — | — | US | disclosed |
| US-20070197492-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070196340-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070184014-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-08-09 | — | — | US | disclosed |
| US-20070093534-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-04-26 | — | — | US | disclosed |
| EP-1622890-A2 | BLOCKERS OF THE QUORUM SENSING SYSTEM OF GRAM-NEGATIVE BACTERIA | 4SC AG (DE) | 2006-02-08 | — | — | EP | disclosed |
| US-20040235914-A1 | Modulation of pathogenicity | 4 SC AG (DE) | 2004-11-25 | — | — | US | disclosed |
| WO-2004099175-A2 | BLOCKERS OF THE QUORUM SENSING SYSTEM OF GRAM-NEGATIVE BACTERIA | 4SC AG (DE) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197492-A1 | Modulation of Pathogenicity | ANTXR2, Q6ZSR9, PGLS | EPHX2 1294/4885NPC1 3826/4885JAK2 894/4885 |
| US-20070203128-A1 | Modulation of Pathogenicity | ANTXR2, Q6ZSR9, PGLS | EPHX2 1294/4885NPC1 3826/4885JAK2 894/4885 |
| US-20070093534-A1 | Modulation of Pathogenicity | NR1H4, NR1I3, NR1H2 | EPHX2 1310/4885NPC1 675/4885JAK2 2967/4885 |
| US-20040235914-A1 | Modulation of pathogenicity | Q6ZSR9, CCL11, CFH | EPHX2 1452/4885NPC1 302/4885JAK2 3251/4885 |
| US-20070208012-A1 | Modulation of Pathogenicity | ANTXR2, Q6ZSR9, PGLS | EPHX2 1294/4885NPC1 3826/4885JAK2 894/4885 |
| US-20100280034-A1 | Modulation of pathogenicity | NR1H4, NR1I3, NR1H2 | EPHX2 1310/4885NPC1 675/4885JAK2 2967/4885 |
| US-20070184014-A1 | Modulation of Pathogenicity | ANTXR2, Q6ZSR9, PGLS | EPHX2 1294/4885NPC1 3826/4885JAK2 894/4885 |
| US-20070196340-A1 | Modulation of Pathogenicity | NR1H4, NR1I3, NR1H2 | EPHX2 1310/4885NPC1 675/4885JAK2 2967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.